Introduction The dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ1–42)
measurement does not parallel to cognitive changes in Alzheimer's disease (AD) and …

The cerebrospinal fluid (CSF) biomarkers amyloid-ß (Aß) 1-42, T-tau, and P-tau have good
diagnostic accuracy for clinically diagnosed Alzheimer's disease (AD). However, in multi …

Introduction Ascertainment of the pattern and temporal change of biomarkers in preclinical
(asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early …

Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …

Cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau have been studied as markers of
Alzheimer's disease (AD). Combined Aβ 42 and t-tau distinguishes AD from healthy controls …

Background: To enhance the accuracy of clinical diagnosis for Alzheimer's disease (AD), pre-
mortem biomarkers have become increasingly important for diagnosis and for participant …

An early and accurate diagnosis of Alzheimer's disease (AD) is required to initiate
symptomatic treatment with currently approved drugs and will be of even greater importance …

Abstract Background In Alzheimer's disease, amyloid-β (A β) peptides aggregate in the
lowering CSF amyloid levels-a key pathological hallmark of the disease. However, lowered …

Background: Although cerebrospinal fluid (CSF) amyloid-β42 peptide (Aβ42) and
phosphorylated tau (p-tau) and blood p-tau are valuable for differential diagnosis of …

Background. According to recent studies, amyloid‐β (Aβ) isoforms as cerebrospinal fluid
(CSF) biomarkers have remarkable predictive value for cognitive decline in the early stages …